DANA P. GOLDMAN BUSINESS ADDRESS … · DANA P. GOLDMAN BUSINESS ADDRESS University of Southern California ... Silverstein A, Brookmeyer R, Goldman D. “The impact of broader hepatitis

Last Saved: August 1, 2017

DANA P. GOLDMAN BUSINESS ADDRESS

University of Southern California Leonard D. Schaeffer Center for Health Policy and Economics 635 Downey Way Los Angeles, CA 90089-3333 e-mail: [email protected] web page: http://healthpolicy.usc.edu

EDUCATION 1994 Ph.D., Economics, Stanford University 1988 B.A., Economics, Summa cum Laude, Cornell University

APPOINTMENTS 2013-Present Leonard D. Schaeffer Director’s Chair

Distinguished Professor of Public Policy, Pharmacy, and Economics (Ophthalmology and Gerontology by courtesy) University of Southern California

2017-Present Nonresident Senior Fellow, Economic Studies Program, Brookings Institution 2005-Present Adjunct Professor, UCLA, Department of Health Policy and Management 2002-Present Research Associate, National Bureau of Economic Research 2009-2013 Director, Leonard D. Schaeffer Center for Health Policy & Economics 2009-2013 Norman Topping Chair in Medicine and Public Policy, University of Southern California 2006-2009 Director, Health Economics, Finance, and Organization, RAND 2003-2009 Distinguished Chair in Health Economics, RAND 1999-2009 Professor of Economics, Pardee RAND Graduate School 2005-2011 Adjunct Professor, UCLA, Radiology 2000-2005 Adjunct Associate Professor, UCLA Health Services and Radiology 1996-2000 Adjunct Assistant Professor, UCLA, Health Services 1994-1996 Visiting Assistant Professor, UCLA, Economics 1998-2002 Senior Economist, RAND 1996-1998 Economist, RAND 1993-1996 Associate Economist, RAND

HONORS AND AWARDS 2017 Associates Award for Creativity in Research*, University of Southern California 2016 Distinguished Professor, University of Southern California 2015 Robert Biller Outstanding Faculty Award, Price School of Public Policy 2012 USC Mellon Mentoring Award 2011 MetLife Foundation Silver Scholar Award 2009 Elected Member, National Academy of Medicine 2009 Eugene Garfield Economic Impact of Medical and Health Research Award 2006 Edwin E. Huddleson, Jr. Outstanding Teacher Award, RAND Graduate School 2002 Annual Research Award, National Institute for Health Care Management 2002 Alice S. Hersh New Investigator Award, AcademyHealth

*Associates awards are “the highest honors the university faculty can bestow on its members for distinguished intellectual and artistic achievements.”

Goldman\2

2000 Article of the Year, Association for Health Services Research 1993 Stanford University Fellowship in Health Care Research and Health Policy 1992 John M. Olin Fellowship for Research in Economic Policy 1988 Summa Cum Laude with Distinction in All Subjects, Cornell University 1988 Phi Beta Kappa, Cornell University 1984 National Merit Scholar

PROFESSIONAL ACTIVITIES Training & Research:

2004-Present Director, Roybal Center for Health Policy Simulation 1996-2013 Director, UCLA/RAND Health Services Research Postdoctoral Training Program 2006-2009 Director, Bing Center for Health Economics, RAND 1997-2007 Director, RAND Summer Institute

Teaching: 2012-Present Health Economics, USC 2010-Present Graduate Seminar in Pharmaceutical Economics and Policy, USC 2009-Present Introduction to Health Policy and Management, USC 1997-2007 Health Economics, Pardee RAND Graduate School 1994-1995 Government Regulation of Labor Markets, UCLA Department of Economics 1994 Introduction to Labor Economics, UCLA Department of Economics 1991 Intermediate Econometrics, Stanford University (teaching assistant)

Editorial Boards: 2012-Present Evidence-Based Diabetes 2012-Present Evidence-Based Oncology 2005-Present Forum for Health Economics and Health Policy (founding co-editor) 2003-Present Health Affairs 2003-Present American Journal of Managed Care 2002-Present B.E. Journals in Economic Analysis and Policy 1996-1998 RAND Journal of Economics

Advisory Panels: 2014-Present Board of Directors, International Society for Pharmacoeconomics and Outcomes Research 2014-Present PhRMA Adherence Advisory Council 2013-Present Hutchinson Institute for Cancer Outcomes Research External Advisory Board (Chair) 2008-Present Board of Directors, American Society of Health Economists 2007-Present MacArthur Foundation, Research Network on an Aging Society 2013-2014 World Economic Forum’s Global Agenda Council on Personalized and Precision Health 2011-2013 World Economic Forum’s Global Agenda Council on Genetics 2009-2010 National Academy of Science, Panel to Improve Medicare Cost Projections (Chair) 2008-2017 Congressional Budget Office, Panel of Health Advisers 2008-2010 National Academy of Science, Fiscal Future of the United States 2006-2008 Institute of Medicine, Committee on the Value of Clinical Services 2005-2009 International Health Economics Association, Scientific Advisory Committee 2007-2008 National Institutes of Health, Special Emphasis Panel 2005-2006 AcademyHealth, Planning Committee for Annual Research Meeting 2005-2006 National Academy of Sciences, Expert Panel on the Future of the NLTCS 2003-2007 National Institute on Aging, Behavior and Social Science of Aging study section

Goldman\3

2002-2005 Berkeley Electronic Press, Board of Directors 2002-2004 Institute of Medicine, Behavioral and Social Sciences in Medical School Curricula 1997-1998 Agency for Health Care Policy and Research, Special Emphasis Panel

Expert Testimony: 2005 California Assembly Health Committee, Sacramento, CA 1993 Senate Labor and Human Resources Committee, Washington D.C. 1992 House Ways and Means Subcommittee on Health, Washington D.C.

Selected Media: Television ABC News (Nightline), CNN World News, CNN Headline News, NBC News with Tom

Brokaw, CBS Nightly News with Dan Rather, CBS Evening News with Katie Couric Radio NPR All Things Considered, KNX, KQED Newspaper Wall Street Journal, Los Angeles Times, New York Times, Washington Post, Miami Herald,

Boston Globe, Boston Herald, San Francisco Chronicle Magazine Business Week, U.S. News & World Report, Time

Professional Organizations:

AEA, PAA, IHEA, ASHEcon, AcademyHealth, ISPOR

PUBLICATIONS Journals 1. Auerbach A, Goldman D, et al. “How the Growing Gap in Life Expectancy May Affect Retirement Benefits and

Reforms.” Nation Bureau of Economic Research, Published online July 2017.

2. Van Nuys K, Chou J, Silverstein A, Brookmeyer R, Goldman D. “The impact of broader hepatitis C treatment strategies on population health and social value in England.” Journal of Hepatology, 66(1):S407-S407, 2017.

3. Zissimopoulos J, Blaylock B, Goldman D, Rowe J. “Raising the Social Security Entitlement Age: Implications for the Productive Activities of Older Adults.” Research on Aging, 39(1)166–189, 2017.

4. Cheng W, Gaudette E, Goldman D. “PCSK9 Inhibitors Show Value for Patients and the US Health Care System.” Value in Health, Published online June 16, 2017.

5. Jena A, Goldman D, Karaca-Mandic P. “Hospital Prescribing of Opioids to Medicare Beneficiaries.” JAMA Internal Medicine, 176(7):990-997, 2016.

6. Woo K, Gascue L, Goldman D, Romley J. “Variations in outcomes of hemodialysis vascular access by race/ethnicity in the elderly.” Journal of Vascular Surgery, 65(3):783-792, 2016.

7. Blumenthal D, Goldman D, Jena A. “Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.” Annals of Internal Medicine, 166(3):219-220, 2017.

8. Agus D, Gaudette É, Goldman D, Messali A. “The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.” PLoS One, Published online November 30, 2016.

Goldman\4

9. Snider J, Seabury S, Lopez J, McKenzie S, Wu Y, Goldman D. “Impact of Type 2 Diabetes Medication Cost-sharing on Patient Outcomes and Health Plan Costs.” American Journal of Managed Care 22(6):433-440, 2016.

10. Jena A, Blumenthal D, Stevens W, Chou J, Ton T, Goldman D. “Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events.” American Journal of Managed Care, 22(6):e199-207, 2016.

11. Goldman D, Gaudette E, Cheng W. “Competing Risks: Investing in Sickness Rather Than Health.” American Journal of Preventive Medicine, 50(5):S45-50, 2016.

12. Goldman D. “The Economic Promise of Delayed Aging.” Cold Spring Harbor Perspectives in Medicine, 6(2):a025072, December 18, 2015.

13. Gaudette E, Tysinger B, Cassil A, Goldman D. “Health and Health Care of Medicare Beneficiaries in 2030.” Forum for Health Economics and Policy, 18(2):75-96, 2015.

14. Romley J, Gong C, Jena A, Goldman D, Williams B, Peters A. “Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.” BMJ, 351:h6334, 2015.

15. Snider J, Goldman D, Rosenblatt L, Seekins D, Juday T, Sanchez Y, Wu Y, Peneva D, Romley J. “The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.” Medical Care Research and Review, 73(3):329-348, 2015.

16. Nikolich-Žugich J, Goldman D, Cohen P, Cortese D, Fontana L, Kennedy B, Mohler M, Olshansky S, Perls T, Perry D, Richardson A, Ritchie C, Wertheimer A, Faragher R, Fain M. “Preparing for an Aging World: Engaging Biogerentologists, Geriatricians, and the Society.” Journal of Gerontology A, 71(4):435-44, 2015.

17. Van Nuys K, Brookmeyer R, Chou J, Dreyfus D, Dieterich D, Goldman D. “Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.” Health Affairs, 34(10):1666-74, 2015.

18. Woo K, Goldman D, Romley J. “Early Failure of Dialysis Access among the Elderly in the Era of Fistula First.” Clinical Journal of the American Society of Nephrology. 10(10):1791-8, 2015.

19. Lakdawalla D, Chou J, Linthicum M, MacEwan J, Zhang J, Goldman D. “Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.” JAMA Oncology, 1(2):196-202, 2015.

20. Turakhia M, Shafrin J, Bognar K, Goldman D, Mendys P, Abdulsattar Y, Wiederkehr D, Trocio J. “Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States.” American Journal of Cardiology, 116(5):733-9, 2015.

21. Dzau V, Ginsburg G, Van Nuys K, Goldman D. “Aligning incentives to fulfil the promise of personalized medicine.” The Lancet, 385(9982):2015-2120, May 6, 2015.

22. Gaudette E, Goldman D, Messali A, Sood N. “Do Statins Reduce the Health and Health Care Costs of Obesity?” PharmacoEconomics, 33(7):723-734, 2015.

23. Seabury S, Lakdawalla D, Dougherty S, Sullivan J, Goldman D. “Medication Adherence and Measures of Health Plan Quality.” American Journal of Managed Care, Published online July 9, 2015.

24. Romley J, Axeen S, Lakdawalla D, Chernew M, Bhattacharya J, Goldman D. “The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization.” Health Services Research, 50(3):883-96, 2015.

Goldman\5

25. Jena A, Ho O, Goldman D, Karaca-Mandic, P. “The Impact of the US Food & Drug AdministrationChloroflurocarbon Ban on Out-of-Pocket Costs & Use of Albuterol Inhalers Among Individuals With Asthma.”JAMA Internal Medicine, 175(7):1171-9, 2015.

26. Eber M, Goldman D, Lakdawalla D, Philipson T, Pritchard D, Huesch M, Summers N, Linthicum M, Sullivan J,Dubois R. “Clinical evidence inputs to comparative effectiveness research could impact the development ofnovel treatments.”Journal of Comparative Effectiveness Research, 4(3):203-213, May 7, 2015.

27. Zissimopoulos J, Goldman D, Olshansky S, Rother J, Rowe J. “Individual & Social Strategies to Mitigate theRisks & Expand Opportunities of an Aging America.”Daedalus, 144 (2):93-102, 2015.

28. Romley J, Goldman D, Sood N. “US hospitals experienced substantial productivity growth during 2002-11.”Health Affairs, 34(3):511-8, 2015.

29. Jena A, Goldman D, Seabury S. “Incidence of sexually transmitted infections after human papillomavirusvaccination among adolescent females.”JAMA Internal Medicine, 175(4):617-23, 2015.

30. Chandra A, Snider J, Wu Y, Jena A, Goldman D. “Robot-assisted surgery for kidney cancer increased access to aprocedure that can reduce mortality and renal failure.”Health Affairs, 34(2):220-8, 2015.

31. Jena A, Prasad V, Goldman D, Romley J. “Mortality and Treatment Patterns Among Patients Hospitalized WithAcute Cardiovascular Conditions During Dates of National Cardiology Meetings.”JAMA Internal Medicine, 175(2):237-44, 2015.

32. Eber M, Goldman D, et al. “Clinical evidence inputs to comparative effectiveness research could impact thedevelopment of novel treatments.”Journal of Comparative Effectiveness Research, 4(3):1-11, 2015.

33. Zissimopoulos J, Joyce G, Scarpati L, Goldman D. “Did Medicare Part D reduce disparities?”American Journal of Managed Care, 21(2):119-28, 2015.

34. Stevens W, Philipson T, Khan Z, MacEwan J, Linthicum M, Goldman D. “Cancer mortality reductions weregreatest among countries where cancer care spending rose the most, 1995-2007.”Health Affairs, 34(4):562-70, 2015.

35. Goldman D and Orszag P. “The Growing Gap in Life Expectancy: Using the Future Elderly Model to EstimateImplications for Social Security and Medicare.”American Economic Review: AEA Papers and Proceedings, 104(5):230-33, 2014.

36. Barcellos S, Wupperman A, Carman K, Bauhoff S, McFadden D, Kapteyn A, Winter J, Goldman D.“Preparedness of Americans for the Affordable Care Act.”Proceedings of the National Academy of Sciences, 111(15):5497-5502, 2014.

37. Romley J, Axeen S, Lakdawalla D, Chernew M, Bhattacharya J, Goldman D. “The Relationship betweenCommercial Health Care Prices and Medicare Spending and Utilization.”Health Services Research, 50(3):883-96, 2015.

38. Jena A, Goldman D, Weaver L, Karaca-Mandic P. “Opioid prescribing by multiple providers in Medicare:retrospective observational study of insurance claims.”BMJ—British Medical Journal, 348:g1393, 2014.

39. Trish E, Joyce G, Goldman D. “Specialty drug spending trends among Medicare and Medicare Advantageenrollees, 2007-11.”Health Affairs, 33(11):2018-24, 2014.

40. Goldman D, Philipson T. “Five myths about cancer care in America.”Health Affairs, 33(10):1801-4, 2014.

Goldman\6

41. Seabury S, Goldman D, Kalsekar et al. “Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.” American Journal of Managed Care, 20(2):e52-60, 2014.

42. Snider J, Juday T, Romley J, Seekins D, Rosenblatt L, Sanchez Y, Goldman D. “Nearly 60,000 uninsured and low-income people with HIV/AIDS live in states that are not expanding Medicaid.” Health Affairs, 33(4):724, 2014.

43. Van Nuys K, Gobe D, Ng-Mak D, Cheung H, Sullivan J, Goldman D. “The association between employee obesity and employer costs: evidence from a panel of U.S. employers.” American Journal of Health Promotion, 28(5):277-85, 2014.

44. Goldman D, Fastenau J, Dirani R et al. “Medicaid Prior Authorization Policies and Imprisonment Among Patients with Schizophrenia.” American Journal of Managed Care, 20(7):577-586, 2014.

45. Snider J, Bognar K, Glob D, Ng-Mak D, Sullivan J, Summers N, Goldman D. “Identifying patients at risk for high medical costs and good candidates for obesity intervention.” American Journal of Health Promotion, 28(4):218-27, 2014.

46. Basu A, Jena A, Goldman D, Philipson T, Dubois R. “Heterogeneity in Action: the Role of Passive Personalization in Comparative Effectiveness Research.” Health Economics, 23(3):359-73, 2014.

47. Romley J, Chen A, Goldman D, et al. “Hospital Costs and Inpatient Mortality among Children Undergoing Surgery for Congenital Heart Disease.” Health Services Research, 49(2):588-608, 2014.

48. Goldman D, Dirani R, Fastenau J, et al. “Do Strict Formularies Replicate Failure for Patients with Schizophrenia?” American Journal of Managed Care, 20(30):219-228, 2014.

49. Goldman D, Juday T, Linthicum M, et al. “The Prospect Of A Generation Free Of HIV May Be Within Reach If The Right Policy Decisions Are Made.” Health Affairs, 33(3):428-33, 2014.

50. Ryan G, Bloom E, Lowsky DJ, et al. “Data-Driven Decision-Making Tools To Improve Public Resource Allocation For Care And Prevention Of HIV/AIDS.” Health Affairs, 33(3):410-7, 2014.

51. Sood N, Juday T, Vanderpuye-Orgle J, Rosenblatt L, Romley JA, Peneva D, Goldman D. “HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care.” Health Affairs, 33(3):394-400, 2014.

52. Romley J, Juday T, Solomon M, Seekins D, Brookmeyer R, Goldman D. “Early HIV Treatment Led To Life Expectancy Gains Valued At $80 Billion For People Infected In 1996-2009.” Health Affairs, 33(3):370-7, 2014.

53. Goldman D, Juday T, Seekins D, et al. “Early HIV Treatment in the United Sates Prevented Nearly 13,500 Infections Per Year During 1996-2009.” Health Affairs, 33(3):362-9, 2014.

54. Lowsky J, Olshansky SJ, Bhattacharya J, Goldman D. “Heterogeneity in Healthy Aging.” Journal of Gerontology, Series A, Biological Sciences and Medical Sciences, 69(6):640-649, 2014.

55. Goldman D, Olshansky SJ. “Delayed Aging Versus Delayed Disease: A New Paradigm for Public Health.” Public Policy & Aging Report, 23(4):16-18, 2013.

56. Goldman D, McFadden D, Newhouse J. “Introduction. American Medicare Program, Parts C and D.” Journal of Health Economics 32(6):1258-1262, 2013.

Goldman\7

57. Joyce G, Zissimopoulos J, Goldman D. “Digesting the Doughnut Hole.” Journal of Health Economics, 32(6):1345-1355, 2013.

58. Goldman D, Cutler D, Rowe J, et al. “Substantial Health and Economic Returns From Delayed Aging May Warrant a New Focus For Medical Research.” Health Affairs, 32(10):1698-1705, 2013.

59. Goldman D, Gupta C, Vasudeva E, et al. “The Value of Diagnostic Testing in Personalized Medicine.” Forum for Health Policy and Economics, 16(20):121-133, 2013.

60. Lakdawalla D, Eber M, Forma F, Sullivan J, Michaud P, Bradley L, Goldman D. “Measuring the Value of Better Diabetes Management.” American Journal of Managed Care, 10(Special Issue 2):SP70-76, 2013.

61. Eibner C, Goldman D, Sullivan J, et al. “Three Large-Scale Changes to the Medicare Program Could Curb its Costs but Also Reduce Enrollment.” Health Affairs, 32(5):891-899, 2013.

62. Romley J, Jena A, O’Leary J, Goldman D. “Spending and Mortality in US Acute Care Hospitals.” American Journal of Managed Care, 19(2):e46-54, 2013.

63. Philipson T, Snider J, Lakdawalla D, Stryckman B, Goldman D. “Impact of Oral Nutritional Supplementation on Hospital Outcomes.” American Journal of Managed Care, 19(2):121-128, 2013.

64. Chernew M, et al. “Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes.” American Journal of Managed Care, 19(2):93-96, 2013.

65. Jena AB, Sun E, Goldman D. “Confounding in the Association of Proton Pump Inhibitor Use with Risk of Community-Acquired Pneumonia.” Journal of General Internal Medicine, 28(2):223-230, 2013.

66. Goldman D, McFadden D, Newhouse JP. “Introduction” in D Goldman, D McFadden, JP Newhouse (eds.) Journal of Health Economics, 32(6), 2013.

67. Romley J, Goldman D, Eber M, et al. “Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis.” American Journal of Managed Care, 18(8):460-464, 2012.

68. Darkow T, MacLean R, Joyce G, et al. “Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia.” American Journal of Managed Care, 18(11 Suppl):s272-278, 2012.

69. Perlroth D, Bhattacharya J, Goldman D, Garber A. “An Economic Analysis of Conservative Management versus Active Treatment for Men with Localized Prostate Cancer.” Journal of the National Cancer Institute Monographs, 45:250-257, 2012.

70. Hagopian K, Goldman D. “The Health-Insurance Solution.” National Affairs, Fall(13):95-111, 2012.

71. Thornton Snider J, et al. “Inhaled Corticosteroids and the Risk of Pneumonia in Medicare Patients with COPD.” Current Medical Research and Opinion, 28(12):1959-1967, 2012.

72. Best J, Romley J, Goldman D, Conrad R, Peters A. “Expenditures for Medicaid Patients Treated with Exenatide Compared with Other Diabetes Management Regimens.” American Journal of Managed Care, 18(8 Suppl): s191-202, 2012.

73. Barcellos S, Goldman D, Smith JP. “Undiagnosed Disease, Especially Diabetes, Casts Doubt on Some of Reported Health ‘Advantage of Recent Mexican Immigrants.’” Health Affairs, 31(12):2727-2737, 2012.

Goldman\8

74. Grabowski D, Lakdawalla D, Goldman D, et al. “The Large Social Value Resulting From Use of Statins Warrants Steps to Improve Adherence and Broaden Treatment.” Health Affairs, 31(10):2276-2285, 2012.

75. Olshansky SJ, et al. “Differences in Life Expectancy due to Race and Educational Differences are Widening, and Many May Not Catch Up.” Health Affairs, 31(8):1803-1813, 2012.

76. Romley J, Goldman D, Solomon M, McFadden D, Peters A. “Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population.” Diabetes Technology & Therapeutics, 14(10):904-911, 2012.

77. Thornton Snider J, Romley J, Wong K, Zhang J, Eber M, Goldman D. “The Disability Burden of COPD.” COPD, 9(5):513-521, 2012.

78. Michaud P, Goldman D, Lakdawalla D, Zheng Y, Gailey A. “The Value of Medical and Pharmaceutical Interventions for Reducing Obesity.” Journal of Health Economics, 31(4):630-643, 2012.

79. Goldman D, Maestas N. “Medical Expenditure Risk and Household Portfolio Choice.” Journal of Applied Econometrics, 28(4):527-550, 2012.

80. Seabury S, Goldman D, Maclean J, Penrod J, Lakdawalla D. “Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates.” Health Affairs, 31(4):691-699, 2012.

81. Romley J, Sanchez Y, Penrod J, Goldman D. “Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.” Health Affairs, 31(4):683-690, 2012.

82. Philipson T, Eber M, Lakdawalla D, Corral M, Conti R, Goldman D. “An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer.” Health Affairs, 31(4):667-675, 2012.

83. Karaca-Mandic P, Jena A, Joyce G, Goldman D. “Out-of-pocket medication costs and use of medications and health care services among children with asthma.” JAMA, 307(12):1284-1291, 2012.

84. Huckfeldt P, Meeker D, Peters A, Guterman J, Diaz G, Goldman D. “Diabetes management for low-income patients in Los Angeles: two strategies improved disease control in the short term.” Health Affairs, 31(1):168-176, 2012.

85. Jena A, Goldman D, Foster S, Califano J. “Prescription medication abuse and illegitimate internet-based pharmacies.” Annals of Internal Medicine, 155(12):848-850, December, 2011.

86. Romley J, Goldman D. “How Costly is Hospital Quality? A Revealed-Preference Approach.” Journal of Industrial Economics, 59(4):578-608, 2011.

87. Vogt W, et al. "Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.” Health Affairs, 30(12):2346-54, 2011.

88. Goldman D, Zissimopoulos J, Lu Y. “Medical Expenditure Measures in the Health and Retirement Study.” Forum for Health Economics and Policy, 14(3):4, February 2011.

89. Joyce G, Carrera M, Goldman D, Sood N. “Physician Prescribing Behavior and its Impact on Patient-Level Outcomes.” American Journal of Managed Care, 17(12):e462-71, 2011.

Goldman\9

90. Hackbarth A, Romley J, Goldman D. “Racial and ethnic disparities in hospital care resulting from air pollution in excess of federal standards.” Social Science and Medicine, 73(8):1163-1168, 2011.

91. Goldman D, Joyce G, Vogt W. “Part D Formulary and Benefit Design as a Risk-Steering Mechanism.” American Economic Review Papers and Proceedings, 101(3):382-386, 2011.

92. Michaud, P, Goldman D. “Differences in Health between Americans and Western Europeans: Effects on Longevity and Public Finance.” Social Science and Medicine, 73(2):254-263, July 2011.

93. Chernew M, Goldman D, Axeen S. “How Much Savings Can We Wring from Medicare?” New England Journal of Medicine, 365(14):e29(1)-e29(3), 2011.

94. Jena A, Goldman D. “Growing Internet Use May Help Explain The Rise In Prescription Drug Abuse In The United States.” Health Affairs, 30(6):1192-1199, June 2011.

95. Baicker K, Goldman D. “Patient Cost-Sharing and Health Care Spending Growth.” Journal of Economic Perspectives, 25(2):47-68, Spring 2011.

96. Goldman D, Smith JP. ”The increasing value of education to health.” Social Science and Medicine, 72(10):1728-1737, 2011.

97. Goldman D, Lakdawalla D, Philipson T. “Market exclusivity for drugs: the authors reply.” Health Affairs, 30(4):799, April 2011.

98. Jena A, Goldman D, Joyce G. “Association Between the Birth of Twins and Parental Divorce.” Obstetrics & Gynecology, 117(4):892-897, April 2011.

99. Romley J, Jena A, Goldman D. “Hospital spending and inpatient mortality: evidence from California: an observational study.” Annals of Internal Medicine, 154(3):160-167, February 2011.

100. Meeker D, Joyce G, Malkin J, Teutsch S, Haddix A, Goldman D. “Coverage and Preventive Screening.” Health Services Research, 46(1p1):173-184, February 2011.

101. Goldman D, Lakdawalla D, Malkin J, Romley J, Philipson T. “The Benefits of Giving Makers Of Conventional ‘Small Molecule’ Drugs Longer Exclusivity Over Clinical Trial Data.” Health Affairs, 30(1):84-90, January 2011.

102. Perlroth D, Garber A, Goldman D. "The Potential Impact of Comparative Effectiveness Research on U.S. Health Care Expenditures." Demography, 47(Supplement):S173-S190, 2010.

103. Goldman D, Vaiana M, Romley J. “The Emerging Importance of Patient Amenities in Hospital Care.” New England Journal of Medicine, 363(23):2185-2187, December 2010.

104. Goldman D, Lakdawalla D, Philipson T, Yin W. “Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.” Health Economics, 19(10):1109-1116, October 2010.

105. Shang B, Goldman D. “Prescription Drug Coverage and Medicare Spending among U.S. Elderly.” The Geneva Papers on Risk and Insurance—Issues and Practice, 35(4):539-567, October 2010.

106. Karaca-Mandic P, Joyce G, Goldman D, Laouri M. “Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis.” Health Services Research, 45(5):1227-1250, October 2010.

107. Jena A, Goldman D, Kamdar A, Lakdawalla D, Lu Y. “Sexually transmitted diseases among users of erectile dysfunction drugs.” Annals of Internal Medicine, 153(1):1-7, July 2010.

Goldman\10

108. Michaud PC, Goldman D, Lakdawalla D, Zheng Y, Gailey A, Vaynman I. “The Fiscal Consequences of Trends in Population Health.” National Tax Journal 63(2):307-330, January 2010.

109. Lakdawalla D, Sun E, Jena A, Reyes C, Goldman D, Philipson T. "An Economic Evaluation of the War on Cancer." Journal of Health Economics, 29(1):333-346, May 2010.

110. Philipson T, Seabury S, Lockwood L, Goldman D, Lakdawalla D. “Geographic Variation in Health Care: The Role of Private Markets.” Brookings Papers on Economic Activity, 1:325-355, Spring 2010.

111. Goldman D, Lakdawalla D. “Can the ACA Improve Population Health?” The Economists’ Voice, 7(5), Article 1, 2010.

112. Goldman D, Jena A, Lakdawalla D, Malin J, Malkin J, Sun E. “The Value of Specialty Oncology Drugs.” Health Services Research, 45(1):115-132, 2010.

113. Sun E, Jena A, Lakdawalla D, Reyes C, Philipson T, Goldman D. “The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000.” Forum for Health Economics & Policy, 13(2), 2010.

114. Antos J, Bertko J, Chernew M, Cutler D, Goldman D, McClellan M, McGlynn E, Pauly M, Schaeffer L, Shortell S. “Bending the Curve: Effective Steps to Address Long-Term Healthcare Spending Growth.” American Journal of Managed Care, 15(10):676-680, 2009.

115. Olshansky J, Goldman D, Zheng Y, Rowe J. “Aging in America in the 21st Century: Demographic Forecasts from the MacArthur Research Network on an Aging Society.” Milbank Quarterly, 87(4):842-862, 2009.

116. Goldman D, Zheng Y, Girosi F, et al. "The Benefits of Risk Factor Prevention in Americans Aged 51 and Older." American Journal of Public Health, 99(11):2096-2101, 2009.

117. Bhattacharya J, Goldman D, Sood N. “Market Evidence of Misperceived Mortality Risk.” Journal of Economic Behavior & Organization 72(1):451-462, 2009.

118. Joyce G, Goldman D, Vogt W, Sun E, Jena A. "Medicare Part D After Two Years." American Journal of Managed Care, 15(8):31-39, 2009.

119. Solomon M, Goldman D, Joyce G, Escarce J. "Cost sharing and the initiation of drug therapy for the chronically ill." Archives of Internal Medicine, 169(8):740-748, 2009.

120. Arrow K et al. "Toward a 21st century health care system: recommendations for health care reform." Annals of Internal Medicine, 150(7):493-495, 2009.

121. Sood N, de Vries H, Gutierrez I, Lakdawalla D, Goldman D. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries.” Health Affairs, 28(1):w125–w137, 2009.

122. Lakdawalla D, Goldman D, Michaud P, et al., "U.S. Pharmaceutical Policy in a Global Marketplace." Health Affairs, 28(1):w138–w150, 2009.†

123. Ruelas V, Roybal G, Lu Y, Goldman D, Peters A. "Clinical and behavioral correlates of achieving and maintaining glycemic targets in an underserved population with type 2 diabetes." Diabetes Care, 32(1):54-56, 2009.

†Awarded the Eugene Garfield Economic Impact Prize.

Goldman\11

124. Goldman D, D McFadden. "Want to Monitor Medicare's New Drug Benefit Program? Start by Sending a Check for $120,000." The Economists' Voice, 5(4), Article 1, 2008.

125. Joyce G, Goldman D, Karaca-Mandic P, Lawless G. "Impact of Specialty Drugs on Use of Other Medical Services." American Journal of Managed Care, 14(12): 821-828, 2008.

126. Goldman D, Joyce, G. "Medicare Part D: A Successful Start With Room for Improvement." JAMA, 299(16):1954-1955, 2008.

127. Goldman D, Jena A, Philipson T, Sun E. "Drug Licenses: A New Model for Pharmaceutical Pricing." Health Affairs, 27(1):122-129, 2008.

128. Kilgore M, Goldman D. "Drug Costs and Out-of-Pocket Spending in Clinical Trials." Contemporary Clinical Trials, 29:1-8, 2008.

129. Shang B, Goldman D. “Does Age or Life Expectancy Better Predict Health Care Expenditures?” Health Economics, 17:487–501, 2008.

130. Goldman D, Philipson T. “Integrated Insurance Design in the Presence of Multiple Medical Technologies.” American Economic Review, 97(2): 427-432, 2007.

131. Garber A, Goldman D, Jena A. "The Promise of Health Care Cost-Containment." Health Affairs, 26(6):1545-1547, 2007.

132. Goldman D, Joyce G, Zheng Y. "Prescription Drug Cost Sharing: Association With Medication and Medical Utilization and Spending and Health." JAMA, 298(1):61-69, 2007.

133. Joyce, G, Goldman D, Karaca-Mandic P, Zheng Y. "Pharmacy Benefit Caps and the Chronically-Ill." Health Affairs, 26(5):1333-1344, 2007.

134. Goldman D, Joyce G, Karaca-Mandic P, Sood N. "Adverse Selection in Prescription Drug Plans." Forum for Health Economics & Policy, 9(1), 2007.

135. Lakdawalla D, Sood N, Goldman D. “HIV Breakthroughs and Risky Sexual Behavior.” Quarterly Journal of Economics, 121(3):1063-1102, 2006.

136. Goldman D, Smith J, Sood N. “Immigrants and the Cost of Medical Care.” Health Affairs, 25(6):1700-1711, 2006.

137. Goldman D, Sood N. "Rising Medical Costs: Are We in Crisis?" Health Affairs, 25(5):w389, 2006.

138. Goldman D, Joyce G, Lawless G, Crown W, Willey V. “Benefit Design and Specialty Drug Use.” Health Affairs, 25(5):1319-1331, 2006.

139. Goldman D, Joyce G, Karaca-Mandic P, Sood N. "Adverse Selection in Prescription Drug Plans." Forum for Health Economics & Policy, 9(1):Article 4, 2006.

140. Goldman, D, Joyce G, Karaca-Mandic P. “Varying Pharmacy Benefits With Clinical Status: The Case of Cholesterol-Lowering Therapy.” American Journal of Managed Care, 12(1):21-28, 2006.

141. Bhattacharya J, Goldman D, McCaffrey D. “Estimating Probit Models with Endogenous Covariates.” Statistics in Medicine, 25(3):389-413, 2006.

142. Goldman D, Cutler D, Shang B, Joyce G. "The Value of Elderly Disease Prevention." Forum for Health Economics & Policy, 9(2):1-29, 2006.

143. Goldman D, Smith J. “Socioeconomic Differences in the Adoption of New Medical Technologies.” American Economic Review Papers and Proceedings, 95(2):234-237, 2005.

Goldman\12

144. Goldman D, Smith J, Sood N. “Legal Status and Health Insurance among Immigrants.” Health Affairs, 24(6):1640-1653, 2005.

145. Goldman D, Lakdawalla D. “A Theory of Health Disparities and Medical Technology.” Contributions to Economic Analysis & Policy: 4(1):1-33, 2005.

146. Goldman D et al. “Consequences of Health Trends and Medical Innovation for the Future Elderly.” Health Affairs, Published online September 26, 2005.

147. Bhattacharya J, Shang B, Su C, Goldman D. “Technological Advance in Cancer and the Future of Medical Care Expenditures by the Elderly.” Health Affairs, W5-R53, 2005.

148. Joyce G, Keeler E, Shang B, Goldman D. “The Lifetime Burden of Chronic Disease among the Elderly.” Health Affairs, W5-R18, 2005.

149. Lakdawalla D, Goldman D, Shang B. “The Health and Cost Consequences of Obesity among the Future Elderly.” Health Affairs, W5-R30, 2005.

150. Chernew M, Goldman D, Pan F, Shang B. “Disability and Health Care Expenditures among Medicare Beneficiaries.” Health Affairs, W5-R42, 2005.

151. Shekelle P, Ortiz E, Newberry S, Rich M, Rhodes S, Brook R, Goldman D. “Identifying Potential Health Care Innovations for the Future Elderly.” Health Affairs, W5-R67, 2005.

152. Goldman D, Sood N, Leibowitz A. “The Reallocation of Compensation in Response to Health Insurance Premium Increases.” Economics Letters, 88(5):147-151, 2005.

153. Goldman D, Joyce G. “Moving Towards Better Formulary Management” [commentary]. American Journal of Managed Care, 11(1):13-15;2005

154. Joyce G, Goldman D, Leibowitz A, Alpert A, Bao Y. “A Socioeconomic Profile of Older Adults with HIV” Journal of Health Care for the Poor and Underserved, 16(1):19-28, 2005.

155. Bhattacharya J, Goldman D, Sood N. “Price Regulation in Secondary Insurance Markets.” Journal of Risk and Insurance, 71(4):643-75, 2004.

156. Goldman D, Joyce G, Escarce J, Pace J, Solomon M, Laouri M, Landsman P, Teutsch S. "Pharmacy Benefits and The Use Of Drugs By The Chronically-Ill.” JAMA, 291(19):2344-50, 2004.

157. Buntin M, Escarce J, Goldman D, Kan H, Laugesen M, Shekelle P. “Increased Medicare Expenditures for Physicians’ Services: What are the Causes?” Inquiry, 41(1):83-94, 2004.

158. Goldman D, Bao Y. “Effective HIV Treatment and the Employment of HIV+ Adults.” Health Services Research, 39(6):1687-1708, 2004.

159. Kan H, Goldman D, Keeler E, Danani N, Melnick G. “An Analysis of Unobserved Selection in an Inpatient Diagnostic Cost Group Model.” Health Services and Outcomes Research Methodology, 4(2):71-91, 2004.

160. Lakdawalla D, Bhattacharya J, Goldman D. “Are the Young Becoming More Disabled?” Health Affairs, 23(1):168-176, 2004.

161. Malkin J, Goldman D, Joyce G. “The Changing Face of Pharmacy Benefit Design.” Health Affairs, 23(1):194-199, 2004.

Goldman\13

162. Goldman D, Leibowitz A, Robalino D. “Employee Responses to Health Insurance Premium Increases.” American Journal of Managed Care, 10(1):41-47, 2004.

163. Bui A, Taira R, Goldman D, Dionisio J, Sayre J, Kangarloo H. “Effect of an Imaging-Based Streamlined Electronic Healthcare Process on Quality and Costs.” Academic Radiology 11(1):13-20, 2004.

164. Bhattacharya J, Cutler D, Goldman D et al. "Disability Forecasts and Future Medicare Costs." Forum for Health Economics & Policy 7:4, 2004.

165. Adams J, Schonlau M, Escarce J, Kilgore M, Schoenbaum M, Goldman D. “Sampling Patients Within and Across Health Care Providers: Multi-Stage Non-nested Samples in Health Services Research.” Health Services and Outcomes Research Methodology, 4(3):151-167, 2003.

166. Bhattacharya J, Goldman D, Sood N. “The Link Between Public and Private Insurance and HIV Related Mortality.” Journal of Health Economics, 22(6):1105-1122, 2003.

167. Bhattacharya J, Goldman D, Lakdawalla D. “Counterpoint: A Response to the Editorials by Manton and Williamson,” Medical Care, 41(1):28-31, 2003.

168. Goldman D. “Evaluating the Total Costs of Cancer” [commentary]. Oncology, 17(1):119-120, 2003.

169. Goldman D, Leibowitz A, Joyce G, et al. “Insurance Status of HIV-infected Adults in the Post-HAART Era: Evidence from the United States.” Applied Health Economics and Health Policy, 2(2):85-90, 2003.

170. Goldman D, Berry S, McCabe M et al. “The Incremental Costs of NCI-Sponsored Clinical Trials.” JAMA, 289(22):2970-2977, 2003.

171. Goldman D, Zissimopoulos JM. “The Distribution of Out-of-Pocket Health Care Expenses Among the Elderly.” Health Affairs, 22(3):194-202, 2003.

172. Lewis J, Kilgore M, Goldman D, et al. "The Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials." Journal of Clinical Oncology, 21(7):1383-1389, 2003.

173. Lakdawalla D, Goldman D, et al. “Forecasting the Nursing Home Population” Medical Care, 41(1):8-20, 2003.

174. Joyce G, Escarce J, Solomon M, Goldman D. “Employer Drug Benefit Plans and Spending on Prescription Drugs.” JAMA, 288(14):1733-1739, 2002.

175. Goldman D, Lakdawalla D. “A New Method for Determining Patient Payments for Outpatient Drugs.” American Journal of Managed Care [commentary], 8(2):125-128, 2002.

176. Goldman D, Smith J. “Can Patient Self-Management Help Explain the SES Health Gradient?” Proceedings of the National Academy of Sciences, 99(16):10929-10934, 2002. ‡

177. Goldman D, Joyce G, Malkin J. “The Costs of a Medicare Prescription Drug Benefit.” Topics in Economic Analysis and Policy, 2(1), 2002

178. Goldman D, Smith J. “Commentary: Methodological Biases in Estimating the Burden of Out-of-Pocket Expenses.” Health Services Research, 35(6):1357-1370, 2001.

‡Awarded the NIHCM Excellence in Research Prize.

Goldman\14

179. Goldman D, Bhattacharya J, McCaffrey D, Duan N, Leibowitz A, Joyce G, Morton S. “The Effect of Insurance on Mortality in an HIV+ Population in Care.” Journal of the American Statistical Association, 96(455):883-894, 2001.

180. Schoenbaum M, Lewis J, Kilgore M, Weidmer B, Berry S, Escarce J, Wagle N, Goldman D. “Using Hospital Tumor Registries to Identify Research Subjects.” Heath Services and Outcomes Research Methodology, 2(1):67-76, 2001.

181. Bozzette S, Joyce G, McCaffrey D, Leibowitz A, Morton S, Berry S, Rastegar A, Timberlake D, Shapiro M, Goldman D. “Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy.” New England Journal of Medicine, 344(11):817-23, 2001.

182. Goldman D. “Costs of Conducting Cancer Clinical Trials.” Managed Care and Cancer, 3(2):14-18, 2001.

183. Goldman D, Bhattacharya J, Leibowitz A, et al. “The Impact of State Policy on the Costs of HIV Infection.” Medical Care Research and Review, 58(1):31-59, 2001

184. Goldman D, Schoenbaum ML, Potosky A, et al. "Measuring the Incremental Cost of Clinical Cancer Research." Journal of Clinical Oncology, 19(1):105-110, 2001.

185. London A, Fleishman J, Goldman D, et al. “Use of Unpaid and Paid Home Care Services Among People with HIV Infection in the US.” AIDS Care, 13(1):99-121, 2001.

186. Hamilton B, Ho V, Goldman D. “Queuing for Surgery: Is the U.S. or Canada Worse Off?” The Review of Economics and Statistics, 82(2):297-308, 2000.

187. Kangarloo H, Valdez J, Yao L, et al. “Improving the Quality of Care Through Routine Teleradiology Consultation.” Academic Radiology, 7(3):149-155, 2000.

188. Zwanziger J, Kravitz R, Hosek S, Sloss E, Sullivan G, Kallich J, Goldman D. “Providing Managed Care Options for a Large Population: Evaluating the CHAMPUS Reform Initiative.” Military Medicine, 165(5):403-410, 2000.

189. Andersen R, Bozzette S, Shapiro M, et al. “Access of Vulnerable Groups to Antiretroviral Therapy Among Persons in Care for HIV in the U.S.” Health Services Research, 35(2):389-416, 2000.

190. Goldman D, Buchanan J, Keeler E. “Simulating the Impact of Medical Savings Accounts on Small Business.” Health Services Research, 35(1):53-75, 2000.

191. Frankel M, Shapiro M, Duan N, et al. “National Probability Samples in Studies of Low-Prevalence Diseases. Part II: Designing and Implementing the HIV Cost and Services Utilization Study Sample.” Health Services Research, 34(5):969-992, 1999.

192. Hernandez J, Coulter I, Goldman D, Freed J, Marcus M. “Managed Care in Dental Markets: Is the Experience of Medicine Relevant?” Journal of Public Health in Dentistry, 59(1):24-32, 1999.

193. Shapiro M, Morton S, McCaffrey D, et al. “Variations in the Care of HIV-Infected Adults in the United States.” JAMA, 281(24):2305-2315, 1999.

194. Joyce G, Goldman D, Leibowitz A, et al. “Variation in Inpatient Resource Use in the Treatment of HIV—Do the Privately Insured Receive More Care?” Medical Care, 37(3):220-227, 1999.

195. Goldman D, Leibowitz A, Buchanan J. “Cost Containment and Adverse Selection in Medicaid HMOs.” Journal of the American Statistical Association, 93(441):54-62, 1998.

Goldman\15

196. Bozzette SA, Berry SH, Duan N, et al. “The Care of HIV-Infected Adults in the United States.” New England Journal of Medicine, 339(26):1897-1904, 1998.

197. Goldman D, Leibowitz A, Buchanan J, Keesey J. “Redistributional Consequences of Community Rating.” Health Services Research, 32(1):71-86, 1997.

198. Keeler E, Malkin J, Goldman D, Buchanan J. “Can Medical Savings Accounts for the Nonelderly Reduce Health Care Costs?” JAMA, 275(21):1666-1671, 1996.

199. Goldman D, Hosek S, Dixon L, Sloss E. “The Effects of Benefit Design and Managed Care on Health Care Costs.” Journal of Health Economics, 14(4):401-418, 1995.

200. Goldman D. “Managed Care as a Public Cost Containment Mechanism.” RAND Journal of Economics, 26(2):277-295, 1995.

201. Klerman J, Goldman D. “Job Loss Due to Health Insurance Mandates.” JAMA, 272(7):552-556, 1994.

202. Goldman D, Clarke A, Garber A. “Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase.” International Journal of Technology Assessment in Health Care, 8(4):583-597, 1992.

Book Chapters and Reports 203. Goldman D, Joyce G. “Consumer Demand and Health Effects of Cost Sharing”

Handbook of Pharmaceutical Economics, Oxford University Press; pp. 365-393, 2012. 204. Goldman D, Lakdawalla D. “Intellectual Property, Information Technology, Biomedical Research, and

Marketing of Patented Products” in M Pauly, T McGuire, P Barros (eds.) Handbook of Health Economics, Volume 2. Waltham, MA: Elsevier; pp. 825-868, 2012.

205. Hurd M, Zheng Y, Girosi F, Goldman D. “The Effects of Tobacco Control Policy on the Social Security Trust Fund” in P Bearman, K Neckerman, L Wright (eds.) After Tobacco: What Would Happen if Americans Stopped Smoking? New York: Columbia University Press; pp. 290-321, 2011.

206. Goldman D, Lakdawalla D, Zheng Y. "Food Prices and the Dynamics of Body Weight" in M Grossman and N Mocan (eds.) Economic Aspects of Obesity. Chicago: University of Chicago Press; pp. 65-90, 2011.

207. Chernew M, Goldman D, Pan F, Shang B. “Disability and Spending Growth” in D Cutler and D Wise (eds.) Health at Older Ages: The Causes and Consequences of Declining Disability Among the Elderly. Chicago: University of Chicago Press, 2009.

208. Garber A and Goldman D. “The Changing Face of Health Care” in H Aaron and W Schwarz (eds.) Coping with Methuselah: The Impact of Molecular Biology on Medicine and Society. Washington, DC: Brookings Institution Press; pp. 105-125, 2004.

209. Bhattacharya J, Cutler D, Goldman D, Hurd M, Joyce G, Lakdawalla D, Panis C, Shang B. “Disability Forecasts and Future Medicare Costs” in D Cutler and A Garber (eds.) Frontiers in Health Policy Research, Volume 7. National Bureau of Economic Research, pp. 75-94, 2004.

210. Goldman D, Sood N, Leibowitz A. “Wage and Benefit Changes in Response to Rising Health Insurance Costs” in D Cutler and A Garber (eds.) Frontiers in Health Policy Research, Volume 8. National Bureau of Economic Research, 2005.

211. Alpert A, Garber A, Goldman D. "Societal Perspective: Comment" in A Futerman and A Zimran (eds.) Gaucher Disease. Boca Raton, Florida: CRC Press; pp. 489-498, 2006.

212. Buntin M, Escarce J, Goldman D, et al. Determinants of Increases in Medicare Expenditures for Physicians’ Services. Technical Review 7. AHRQ Publication No. 04-0008, 2003.

Goldman\16

Reviews, Op/Ed, and Letters 1. Goldman D, Lakdawalla D. “Take Me Out to the Pill Game.”

The Wall Street Journal, June 19, 2017. 2. Goldman D, Jena A. “Value-based drug pricing makes sense, but is difficult to pull off.”

STAT, June 8, 2017. 3. Hagopian K, Goldman D. “How To Insure Everyone At A Reasonable Cost.”

Forbes, March 3, 2017. 4. Schaeffer L, Goldman D. “California provides model to replace the Affordable Care Act.”

The Sacramento Bee, February 14, 2017. 5. Goldman D, Lakdawalla D. “Why academics consulting with industry on health care may be an idea whose

time has come.” The Conversation, December 21, 2016.

6. Goldman D, Lakdawalla D. “Election Verdict: Pharma Needs A New Prescription.” STAT, November 10, 2016.

7. Goldman D, Nussbaum S, Linthicum M. “Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement.” Health Affairs Blog, September 15, 2016.

8. Goldman, D. “To Prevent Another EpiPen Controversy, the Government Should Step In.” STAT, August 26, 2016.

9. Goldman D. “Hospital Care for Those Who Can Afford It Helps Care for Those Who Can’t.” The New York Times, August 22, 2016.

10. Goldman D. “Commentary: To ensure access to generic drugs, take a lesson from vaccines.” Modern Healthcare, June 29, 2016.

11. Goldman, D. “Commentary: Drop Medicaid ‘best price’ drug rules in favor of value-based strategies.” Modern Healthcare, November 18, 2015.

12. Romley J, Goldman D, Sood N. “Hospital Productivity: The Authors Reply.” Health Affairs, 34(6):1069, 2015.

13. Goldman D, Lakdawalla D. “Moving Beyond Price-Per-Dose In The Pharmaceutical Industry.” Health Affairs Blog, September 30, 2015.

14. Chandra A, Goldman D. “Understanding Health Care’s Short-Termism Problem.” Harvard Business Review, Published online September 28, 2015.

15. Goldman D, Lakdawalla D, Newcomer L. “It’s Time For Value-Based Payment In Oncology.” Health Affairs Blog, April 28, 2015.

16. Goldman D et al. “Mortality Versus Survival In International Comparisons Of Cancer Care.” Health Affairs Blog, March 20, 2015

17. Altman D, Goldman D. “Medicare Spending Cuts and Hospital Productivity Gains.” The Wall Street Journal, published online Feb 25, 2015.

18. Goldman D, Chandra A, Lakdawalla D. “It’s Easier to Measure the Cost of Health Care than Its Value.” Harvard Business Review, Published online November 18, 2014.

19. Basu A, Jena A, Goldman D, Philipson T, Dubois R. “Response to Epstein on ‘Heterogeneity in Action.” Health Economics, January 21, 2014.

20. Hagopian K and Goldman D. “How To Achieve Universal Health Coverage at Half the Cost.” Forbes Opinion, January 10, 2014.

21. Goldman D, Chernew M, Jena AB. “Health Insurance Exchanges May Be Too Small to Succeed.” New York Times, November 23, 2012.

Goldman\17

22. Seabury S, Lakdawalla D, Goldman D. “Patients’ Willingness To Pay: The Authors Reply.” Health Affairs, 31(8): 1909, 2012.

23. Eber M, Goldman D, Lakdawalla D, Philipson T. “When Epidemiology Goes Astray: Valuing Cancer Care in the United States and Europe.” Health Affairs Blog, May 14, 2012.

24. Schaeffer L, Goldman D. “Benefit Design Should Reflect Value.” Institute of Medicine Commentary, January 27, 2012.

25. Smith P, Goldman D. “Can patient self-management explain the health gradient? Goldman and Smith (2002) revisited: A Response to Maitra.” Social Science & Medicine, 70(1):813-815, 2010.

26. Goldman D and Shah V. “Congress and Medicare.” Huffington Post, May 31, 2011.

27. Goldman D and Edlin A. “Can Immigrants Solve Our Health Care Problems?” New York Times, January 19, 2010.

28. Goldman D. "I am a Death Panelist. I am not the Problem." New York Times, December 9, 2009.

29. Goldman D. "Fix the Healthcare System (and Fight the Recession, Too)." CNN.com, August 21, 2009.

30. Goldman D. "Improve Health, Not the Health Care System." New York Times, June 23, 2009.

31. Goldman D. "Limiting Treatment to Those Who Need It." KQED Healthy Ideas, April 29, 2009.

32. Goldman D. “Half Right.” Cato Unbound, September 14, 2007.

33. Buntin M, Escarce J, Goldman D. “Use of Physician Services for Medicare Beneficiaries.” New England Journal of Medicine, 357(6):617-619, 2007.

34. Goldman D. “Review of ‘Shredding the Social Contract: The Privatization of Medicare’ by John Geyman” New England Journal of Medicine, 355(2): 217-218, 2006.

35. Goldman D, Malkin J. “The HSA Mirage” United Press International, February 20, 2006.

36. Goldman D. “Pressure from rising health-care costs: How can consumers get relief?” Riverside Press Enterprise, October 24, 2005.

37. Goldman D and Schuster M. “Outside View: Health Costs of Katrina” United Press International, October 10, 2005.

38. Goldman D. “Review of ‘Who Should Pay for Medicare?’ by Daniel Shaviro” New England Journal of Medicine, 351:405-407, 2004.

39. Goldman D, Joyce G. “Take Two Aspirin and Call Congress.” Los Angeles Times, December 11, 2002.

40. Wagle N, Goldman D, Kilgore M. "Surveys identify barriers to participation in clinical trials." Journal of the National Cancer Institute, 93(3):238-239, 2001.

41. Goldman D, Joyce G. “A Third—and Better—Way for Prescription Drug Coverage” Los Angeles Times, November 5, 2000.

Goldman\18

GRANTS AND CONTRACTS (PI and co-PI activities only)

2004-2019 Title: Roybal Center for Health Policy Simulation PI Sponsor: National Institute on Aging (P30AG024968) Amount: $2,176,534

2013-2018 Title: Transforming Research and Clinical Knowledge in Traumatic Brain Injury II PI Sponsor: NINDS (U01) Amount: $770,663

2012-2017 Title: Resource Center for Minority Aging Research PI Sponsor: National Institutes of Health (P30AG043073) Amount: $2,345,183

2014-2016 Title: Technological Innovation in Health Care and the Long-Term Outlook Sponsor: National Institutes of Health Amount: $242,971

2011-2016 Title: An Economic and Behavioral Evaluation of Medicare Part D PI Sponsor: National Institute on Aging (P01AG033559) Amount: $1,931,757

2012-2015 Title: MacArthur Foundation Research Network on Aging Society PI Sponsor: MacArthur Foundation Amount: $500,750 2011-2015 Title: Trajectories and Palliation Study (TAPS) PI

Sponsor: RAND Corporation Amount: $241,458

2010-2013 Title: The Science of Medicare Reform CO-PI Sponsor: National Institutes of Health (RC4AG039036) Amount: $5,500,668

2008-2013 Title: Improving Pharmacy Benefit Design PI Sponsor: National Institute on Aging (R01AG029514) Amount: $825,770

2010-2012 Title: Aging Society Benefits and Cost of Interventions PI Sponsor: MacArthur Foundation Amount: $431,623 2009-2012 Title: Economics of Treating Viral STIs PI

Sponsor: National Institutes of Health (5R01HD054877) Amount: $498,726

2009-2012 Title: Private Insurance and Prescription Outcomes for Children PI Sponsor: National Institutes of Health (5R03D058203) Amount: $118,906

2009-2012 Title: Quality of Life and Productivity PI Sponsor: InHealth

Amount: $879,808 2007-2012 Title: Robust Integration Modeling of Health, Wealth and Disability

Sponsor: National Institute on Aging (1R01AG030824) Amount: $2,929,374

Goldman\19

2006-2012 Title: Obesity Among Older Americans PI Sponsor: National Institute on Aging (R01AG025743) Amount: $234,072

2009-2011 Title: A Patient Centered Diabetes Registry PI Sponsor: Institute for Health Technology Studies

Amount: $879,807 2003-2011 Title: Education, Self-Management, and Adherence

Sponsor: National Institute on Aging (5R01AG023363) Amount: $1,692,176

2000-2008 Title: Mini-Medical School for Social Scientists PI Sponsor: National Institute on Aging (5R13AG018327) Amount: $245,850 2006-2007 Title: Understanding How Cost-Sharing Affects Use of Specialty Drugs

Sponsor: Genentech Amount: $300,000

2003-2007 Title: An Investigation of the Viatical Settlements Market PI Sponsor: National Institute on Aging (5R01AG022351) Amount: $948,999

2005-2007 Title: Public Policy and Pharmaceutical Innovation Around the World Sponsor: Pfizer Incorporated Amount: $1,900,000

2005-2005 Title: Snapshot of Medicare and Medicare Consumers in California Sponsor: California Healthcare Foundation Amount: $95,150

2005 Title: Economic Consequences of Medical Research Sponsor: NIH (Office of the Director) Amount: $99,903

2004-2005 Title: Costs of Treating Chronic Disease in the United States and Germany Sponsor: Techniker Krankenkasse Amount: $250,000

2004-2005 Title: The Impact of Cost-Sharing on the Severely Ill Sponsor: Amgen, Inc. Amount: $324,665

2003-2005 Title: Immigrants’ Low Rates Of Health Insurance Sponsor: University of Michigan Amount: $104,351

2001-2005 Title: State and Federal Policy and Outcomes for HIV+ Adults PI Sponsor: Agency for Healthcare Research and Quality (1R01HS010846) Amount: $741,722

2003 Title: The Consequences of Premium Regulation in California Sponsor: California Health Care Foundation Amount: $95,000

Goldman\20

2002-2003 Title: Responsiveness of Drug Expenditures to Drug Benefit Changes Sponsor: Merck & Co, Inc. Amount: $75,000

2000-2003 Title: Impact of Drug Benefit Design on Health Care Costs Sponsor: California Healthcare Foundation Amount: $92,134

2000-2001 Title: The Impact of Prescription Drug Benefits Sponsor: California Healthcare Foundation Amount: $698,917

1999-2003 Title: Health Status and Medical Treatment of the Future Elderly: Implications for Medicare Program Expenditures Sponsor: Center for Medicare and Medicaid Services Amount: $1,260,259

1999-2002 Title: Cost of Cancer Treatment Study Sponsor: NIH, NCI, and NSF Amount: $3,118,310

1999-2002 Title: Insurance Choices in the Medicare Population Sponsor: National Institute on Aging Amount: $648,406

1998-2002 Title: Evaluation of the Medicare/DoD Subvention Demonstration Sponsor: Health Care Financing Administration Amount: $1,411,439

1998 Title: Feasibility Study to Measure the Cost of Cancer Trials Sponsor: National Cancer Institute and National Science Foundation Amount: $400,000

1993-1994 Title: HMO Cost Performance: A Simultaneous Equations Approach Sponsor: Agency for Health Care Policy and Research Amount: $22,000

OTHER ACTIVITIES Selected Lectures and Seminars

Harvard Executive Forum, Boston, MA, November 2015 The Hill - The Future of Specialty Drugs, Washington, DC, October 2015 FH Foundation Global meeting, Pasadena, CA, September 2015 BIO International Convention, Philadelphia, PA, June 2015 Brookings Institution – The Future of Medicare, Washington, DC, June 2015 Roche Spain (Omniprex Conference), San Francisco, CA, May 2015 ISPOR, Philadelphia, PA, May 2015 UC Irvine Board, Irvine, CA, April 2015 AMCP Annual Meeting, San Diego, CA, April 2015 Gilead Health Policy Advisory Board, Foster City, CA, February 2015 USC Keck Department of Preventive Medicine, Los Angeles, CA, February 2015 Claremont Graduate University, Claremont, CA, February 2015. AbbVie, Chicago, IL, January 2015 CHI Annual Meeting, Palo Alto, CA, November 2014.

Goldman\21

BMS-Wharton, Princeton, NJ, November 2014. The Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, November 2014. Brookings Panel, Washington, DC, October 2014. Novartis, New York, NY, September 2014. Edwards Lifesciences, Irvine, CA, September 2014. Brown University, Providence, RI, August 2014. Congressional Diabetes Caucus Briefing, Washington, DC, July 2014. ISPOR, Montreal, QC, Canada, June 2014. Miraval Institute at the University of Arizona, April 2014. USC President’s Leadership Council, April 2014. Health Affairs Issue Briefing, March 2014. University of California, Los Angeles, CA, November 2013. UC Irvine Center for Economics & Public Policy, Irvine, CA, November 2013. Organization for Economic Cooperation and Development (OECD), Paris, France, July 2013. Patient-Centered Diabetes Care Symposium, Chicago, IL, June 2013. The Paul F. Glenn Symposium on the Biology of Aging, Santa Barbara, CA, June 2013. International Society For Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans, LA, May 2013. UC Berkeley Health Services Research Colloquium, Berkeley, CA, March 2013. Covered California: The Challenges and Opportunities of California’s Health Benefit Exchange Panel, Sacramento, CA, February 2013. White House-Stanford University National Health Research Policy Dialogue: Mobilizing Science and Technology to Lower Costs and Improve Outcomes, Palo Alto, CA, January 2013. Centers for Medicare & Medicaid Services, San Francisco, CA, November 2012. California Healthcare Institute: Uniting Science & Policy to Advance Cancer Care, Los Angeles, CA, July 2012. Global Health Care Regulation and Innovation Conference, Beijing, China, June 2012. Health Affairs Briefing: Value in Cancer Care, Washington, DC, April 2012. FRESH Thinking: Overcoming Obstacles to Rapid Diffusion of Cost-Effective Care, Stanford, CA, February 2012. Science of Medicare Reform Symposium, University of Southern California, Los Angeles, CA, January 2012. RAND Conference on Health, Aging and Human Capital, Santa Monica, CA, December 2011. USC-Princeton Value of Innovation in Cancer Care Conference, Princeton, NJ, November 2011. MacArthur Network for an Aging Society, Boston, MA, November 2011. World Economic Forum’s Global Agenda Council on Genetics, Abu Dhabi, United Arab Emirates, October 2011. Russell Sage Foundation, September 2011. AcademyHealth Annual Research Meeting, Seattle, Washington, June 2011. MacArthur Network for an Aging Society, New York, NY, June 2011. Engelberg Center for Health Care Reform at Brookings, Washington, DC, April 2011. University of Southern California Board of Trustees Meeting, Los Angeles, CA, 2011. University of Southern California Health Policy Forum, Washington, DC, March 2011. Ralph Ellison Medical Foundation, Bethesda, MD, March 2011. MacArthur Network for an Aging Society, Palo Alto, CA, February 2011. Stanford University, February 2011. University of Southern California School of Pharmacy 16th Annual Winter Retreat, Napa, CA, January 2011. American Economic Association, Denver, CO, January 2011. NAE Grand Challenges National Summit, University of Southern California, Los Angeles, CA, October 2010. SPPD Sacramento/USC Office of Government and Civic Engagement, Sacramento, CA, September 2010. American Society of Retinal Specialists Annual Meeting, Vancouver, BC, August 2010. Techonomy Conference, Lake Tahoe, CA, August 2010. Novartis Pharmaceuticals Corporation Evidence Based Medicine Roundtable, Newark, NJ, June 2010.

Goldman\22

Lusk Center for Real Estate Annual Spring Retreat, Santa Barbara, CA, May 2010. University of Southern California Athenian Society Dean’s Speaker Series Health Policy Panel, Los Angeles, CA, April 2010. University of Southern California Conference on America’s Looming Fiscal Crisis, Los Angeles, CA, January 2010. ALOUD at Central Library Series with Atul Gawande, Los Angeles, CA, January 2010. Warburg Pincus Health Reform Roundtable, New York, NY, October 2009. UCLA Anderson School’s Annual Board of Visitors Retreat, CA, September 2009. NIH Symposia Series: Understanding Factors that Influence Health through the Tools of the Social Sciences, September 2009. University of Southern California, April 2009. Brown University, February 2009 University of California, San Francisco, January 2009 American Economic Association, January 2009 Pacific Business Group on Health, Half Moon Bay, CA, June 2008 National Academies Presidents' Circle, Washington, DC, May 2008 Brookings Institution, Washington, DC, March 2008 Physician Insurers Association of America, Seattle, WA, May 2007 Federal Reserve Bank of San Francisco, San Francisco, CA, May 2007 Rice University, James A. Baker III Institute for Public Policy, Houston, TX, February 2007 Genentech, San Francisco, CA, February 2007 MacArthur Foundation Initiative on an Aging Society, New York, NY, February 2007 Cedars Sinai Medical Center, Bioethics Seminar, Los Angeles, CA, February 2007 University of California, Berkeley, Mind the GAP Conference, December 2006 Amgen Value in Oncology Summit, San Francisco, CA, December 2006 RAND Health Board of Advisors Meeting, New York, NY, September 2006 University of Southern California, School of Gerontology, September 2006 National Bureau of Economic Research, Cambridge, MA, November 2005 University of California, Los Angeles, November 2005 University of Southern California, Los Angeles, CA, October 2005 Alliance for Healthcare Reform, Washington, DC, September 2005 California Policy Institute, Sacramento, CA, September 2005 Amgen Payer Advisory Board, Los Angeles CA, December 2004 National Press Foundation, University of California, San Diego, August 2004 Pfizer International Advisory Council, Berlin, Germany, June 2004 Dorsey Hughes Symposium, Beaver Creek, Colorado, July 2004 Coalition for the Advancement of Health Through Behavioral and Social Sciences Research, Washington DC, March 2004 Health Insurance Forum, First United Methodist Church, Santa Monica, CA, February 2004 University of California AIDS Research Program Annual Meeting, Los Angeles, February 2004 Balancing the Rx Cost Benefit Equation, USC, Santa Monica CA, December 2003 Center for Health Policy, Stanford University, Palo Alto, June 2003 National Bureau of Economic Research, Cambridge, November 2002 Seminar on Pharmaceutical Economics and Policy, UCLA, Los Angeles, October 2002 Education and Health Conference, Princeton University, Princeton NJ, October 2002 Brookings Institution, Washington DC, April 2002 American Enterprise Institute, Washington DC, April 2002 RAND Board of Governors, Santa Monica CA, April 2002

Goldman\23

Nuffield Trust, London, February 2002 UCLA Pharmacoeconomics Seminar, Los Angeles, April 2002 United Kingdom Treasury Workshop, London, September 2001 Annual Meeting of the Association for Health Services Research, Atlanta, June 2001 12th Annual Health Economics Conference, Duke University, Durham NC, June 2001 Division of General Internal Medicine, UCLA, Los Angeles, June 2001 NIA Health Disparities Workshop, University of Southern California, Los Angeles, May 2001 Center for Health Policy, Stanford University, Palo Alto CA, 2001 Association of Community Cancer Centers; Long Beach CA, 2000 National Bureau of Economic Research Summer Institute; Cambridge MA, 1999 Division of General Internal Medicine, UCLA, Los Angeles, 1999. Association of Health Services Research Annual Meeting, Chicago, 1999 10th Annual Health Economics Conference, University of California, Berkeley CA, 1999 Department of Health Policy and Management, Harvard University, Cambridge MA, 1998 Division of Health Management and Policy, University of Minnesota, Minneapolis, 1998 Division of General Internal Medicine, UCLA, Los Angeles, 1998 Lister Hill Center for Health Policy, University of Alabama, Birmingham, 1998 Department of Health Policy and Management, University of North Carolina, Chapel Hill, 1998 Department of Economics, Duke University, Durham NC, 1997 National Bureau of Economic Research Summer Institute, Cambridge MA, 1996 Department of Economics, University of California, Berkeley California, 1996 Department of Economics, Columbia University, New York City, 1996 Irving B. Harris Graduate School of Public Policy, University of Chicago, Chicago, 1996 American Economic Association Annual Meeting, 1996 International Conference on Health Policy Research, Cambridge MA, December 1995 Econometric Society Seventh World Congress, Tokyo, August 1995 6th Annual Health Economics Conference, University of Michigan, Ann Arbor, June 1995 Department of Health Policy and Management, Johns Hopkins University, Baltimore, 1994 Chief Executive Officer Forum, Witt/Kieffer, San Francisco, December 1994 RAND Board of Trustees, Santa Monica CA, November 1994. Association of Public Policy Analysis and Management Annual Meeting, Chicago, 1994 5th Annual Health Economics Conference, University of Pennsylvania, Philadelphia, June 1994 Conference on Health Care in the 90s: The Economic Impact of Health Care Reform on California, Symposium, San Francisco, November 1993 National Bureau of Economic Research Summer Institute, Cambridge MA, August 1993

Dissertation Committees Sarah Axeen* Title: Data Watch: Use of Prescription Opioids by Medicare Beneficiaries Year: 2015 Position: TBD Lauren Scarpati Title: Essays in Health Economics: Evidence from Medicare Year: 2015 Position: Associate, Analysis Group Barbara Blaylock Title: Essays on the Use of Microsimulation for Health and Economic Policy Analysis

Goldman\24

Year: 2015 Position: Health Economist, OECD Margaret Blume-Kohout Title: Essays on Government Policy and Pharmaceutical Innovation Year: 2009 Position: Visiting Assistant Professor of Economics, Colgate University Yang Lu Title: Three Essays on Health Behaviors and the Need for New Policy Year: 2009 Position: Assistant Professor, Division of General and Emergency Pediatrics, Harbor-UCLA Pediatrics Yuhui Zheng Title: Economic Determinants of Obesity Among Older Americans Year: 2008 Position: Research Scientist, China Medical Board, Tsinghua University, Environmental Defense Fund Serhii Ilchuk Title: Retirement Decisions of Women in Response to Spousal Health Year: 2005 Position: Visiting Professor, University of Kiev School of Public Health Baoping Shang** Title: Effects of Prescription Drug Coverage on Medicare Beneficiaries Year: 2005 Position: International Monetary Fund Matthew Solomon* Title: The Effects of Pharmacy Benefits on Persons with Chronic Disease Year: 2005 Position: Fellow in Cardiovascular Medicine, Stanford University Yuhua Bao Title: Estimating Effects of Pharmaceutical Innovations on Patients’ Employment Outcomes Year: 2003 Position: Associate Professor of Healthcare Policy and Research, Cornell University Neeraj Sood Title: Economics of Viatical Settlements Year: 2003 Position: Vice Dean for Research, USC Price School of Public Policy; Associate Professor, USC School Pharmacy; Director of Research, USC Schaeffer Center Hongjun Kan* Title: Does the Medicare diagnostic cost group model adequately adjust for selection bias? Year: 2002 Position: Global Epidemiology and Health Outcomes, Bristol-Myers Squibb Meredith Kilgore* Title: Cancer Clinical Trials: Effects of Trial Design on Participation and of Participation on Costs, with an

Examination of Cost Analysis Methods and Data Sources Year: 2002 Position: Professor and Chair, University of Alabama-Birmingham School of Public Health Moira Inkelas* Title: Incentives in a Specialty Carve-out Year: 2000 Position: Associate Professor, UCLA School of Public Health

Goldman\25

Leo Morales* Title: Assessing Patient Experience with Healthcare in Multicultural Settings Year: 2000 Position: Associate Professor, UCLA School of Medicine; Faculty, BWF-IT-MD, Center for Metabolic Disease

Prevention *Recipient of AHRQ dissertation grant**Recipient of Pardee RAND Graduate School Hagopian Award

DISCLOSURE

Dr. Goldman serves as a consultant to Precision Health Economics, a health care consultancy that provides services to health insurance, pharmaceutical, biologic and health care technology companies, and holds equity in its parent company, Precision Medicine Group.